1.74
+0.2(+12.99%)
Currency In USD
| Previous Close | 1.54 |
| Open | 1.53 |
| Day High | 1.84 |
| Day Low | 1.52 |
| 52-Week High | 2.48 |
| 52-Week Low | 0.77 |
| Volume | 10.14M |
| Average Volume | 3.64M |
| Market Cap | 183.4M |
| PE | -6.21 |
| EPS | -0.28 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 1.61 |
| Change | 0.2 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of December 04, 2025 at a share price of $1.74. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $450.78 as of December 04, 2025 at a share price of $1.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indica
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
GlobeNewswire Inc.
Oct 22, 2025 1:00 PM GMT
Company to conduct 1x1 meetings with investors on Wednesday, November 12thNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focus